Articles

What benefits can be obtained from duodenal mucosal resurfacing?

Study finds improvement in pain relief and sleep patterns

Friend of Diabetes in Control and frequent guest author David Kliff, Diabetic Investor, shared his views on some of the news coming out of EASD. As always, his ideas are thought-provoking. We reached out to some of our Advisory Board members to get their responses to David’s piece, and they provided additional strong viewpoints for your consideration.

What should be the proper treatment selection for patients with type 2 diabetes?

Scientists believe drug commonly prescribed for T2 could be routinely taken by T1 patients.

What benefits can lixisenatide provide when added to basal insulin regimen?

Empagliflozin might not only decrease the risk of cardiovascular events in patients with type 2, but also renal events.

Could GLP-1 inhibitors be a useful adjunct therapy in type I diabetes?

Starting patients diagnosed within the last 7 years on 2-4 weeks of intensive insulin therapy could help keep them off additional medications for at least 48 weeks.

Studies suggest fenofibrate can prevent microvascular changes, decrease need for surgery.